India's Drug Registry Builds the Data Spine Its Pharmaceutical Ambitions Require

The problem was hiding in plain sight for years. Walk into a government hospital in Patna, a private clinic in Bengaluru, and a pharmacy management system in Hyderabad, and the same molecule — say, metformin — might appear under three different names, four different dose formats, and two different manufacturer codes. No one was lying. Everyone was simply recording what their own system knew. The result was a fractured data landscape that cost patients, confused clinicians, and handed auditors nothing they could reconcile.

On Monday, the Union government launched the Drug Registry, a centralised digital database designed to end that confusion. Unveiled by Union Health Minister Jagat Prakash Nadda and developed jointly by the Central Drugs Standard Control Organization (CDSCO) and the National Resource Centre for EHR Standards (NRCeS) in Pune, the registry gives India's nearly $50-billion pharmaceutical market something it has never had: a single, verified reference point for every medicine in circulation.

What the Registry Actually Does

The platform lets any user — clinician, pharmacist, software developer, supply-chain manager — search a drug by its generic name, brand name, active substance, or manufacturer. The Ministry of Health described the core failure the registry addresses without ambiguity: "Medicines are one of the most critical data elements in healthcare delivery. However, across healthcare systems in India, the same drug is often represented using different names and formats, leading to inconsistencies, duplication, data entry errors, and lack of interoperability."

At launch, the registry carries more than 123,000 branded drugs, 10,000-plus generic drugs, and 29,000-plus substances. These represent the scope of what a pharmacist, doctor, or hospital information system will query on day one.

The registry does not operate in a proprietary silo. It is built on SNOMED CT, the internationally recognised clinical terminology standard, which means drug codes in an Indian hospital management system can be read and validated by systems in London or Nairobi without a translation layer. The design integrates with Hospital Management Information Systems, e-prescription platforms, and all ABDM-compliant digital health applications.

The Infrastructure Beneath the Infrastructure

Conceptualised under the Ayushman Bharat Digital Mission, the Drug Registry is not a standalone project. It is what engineers call a foundational layer — the data infrastructure on which higher-order applications, such as e-prescriptions, insurance claims, and pharmacovigilance alerts, must rest to function without contradiction. Without it, ABDM's Health ID, its Health Facility Registry, and its Health Professional Registry are each individually coherent but collectively fragmented. Drug data is the connective tissue; without standardisation at that level, a patient's digital health record is only as reliable as the weakest nomenclature in the chain.

The ministry's own framing made this dependency explicit: inconsistent drug naming creates "challenges in clinical decision-making, e-prescriptions, supply chain management, and continuity of care." The registry, described as a "single source of truth," is designed to resolve all four. Nadda also unveiled four other digital health initiatives under ABDM at the same event, signalling that the government treats Monday's launch as an acceleration, not a standalone milestone.

The Export Dimension

India's pharmaceutical industry — dominant in global generics, with roughly half its output headed to export markets — operates under intensifying data scrutiny from regulators in the United States, the European Union, and WHO prequalification programmes. The US FDA's data integrity inspections of Indian manufacturing facilities have historically focused on documentation and record-keeping. Regulatory pressure is now moving upstream: regulators increasingly want to verify that the drug leaving an Indian plant corresponds precisely to the drug recorded in the country's own nomenclature and coding systems.

A national drug registry aligned with SNOMED CT is an offensive trade instrument as much as a domestic health reform. When an EU pharmacovigilance authority queries whether a molecule sold in Germany corresponds to the molecule coded in the originating country's health system, India can now answer with a standardised, machine-readable reference. Countries that cannot answer that question cleanly face non-tariff friction that no bilateral trade agreement can fully dissolve.

Analysts working on India's pharmaceutical export credibility have noted that domestic regulatory data quality is the variable most likely to determine future market access — not tariffs, not logistics, but data. The Drug Registry moves India's position on that variable materially.

The Fraud Reduction Calculus

Inside India, the registry's most immediate economic consequence may be in the health insurance architecture. The Pradhan Mantri Jan Arogya Yojana runs one of the world's largest government health insurance schemes by beneficiary count, and fraudulent billing — including inflated drug charges and phantom prescriptions — has been identified by the National Health Authority as a systemic cost pressure on the programme's finances.

Interoperability between ABDM's drug data layer and the claims-processing systems beneath PMJAY creates an audit trail that did not exist before. A claim for a high-value medicine can be cross-referenced against the registry's standardised code; a medicine recorded under a variant name that does not resolve to a verified entry flags for review. The mechanism is not foolproof — sophisticated fraud adapts — but it raises the cost of routine billing manipulation in a way that aggregate watchlists and manual audits cannot.

This matters to ordinary Indian households as arithmetic. Out-of-pocket expenditure still accounts for a substantial share of total health spending in India. Every rupee recovered from fraudulent claims is a rupee that extends the effective coverage of a scheme designed to protect families from catastrophic medical costs. The Drug Registry does not solve that problem by itself, but it removes one of the structural enablers of the leakage.

The Data Governance Question

Centralising drug data under a government-controlled registry carries risk. Technology-policy analysts have flagged the governance architecture as the variable that will determine whether the registry strengthens or undermines trust in the broader ABDM ecosystem. A centralised database of medicine usage patterns, linked to Health IDs and prescription records, is a sensitive asset. Its integrity depends on access controls, audit mechanisms, and a clear legal framework governing who can query it, under what conditions, and with what accountability.

India's Personal Data Protection framework, still in its implementation phase, will need to extend explicit protections to health data flowing through ABDM-linked systems. The Drug Registry is technically ready; the governance layer around it remains incomplete. Foreign regulators considering India's digital health infrastructure as a model — the WHO's Global Initiative on Digital Health has already engaged with India's stack — will ask that question before endorsing it. Answering it well is both a domestic obligation and a soft-power opportunity.

A Foundational Bet on Digital Health

The Parliamentary Standing Committee on Health identified the absence of a unified drug formulary as a barrier to effective PMJAY implementation in its 2023 report. Monday's launch addresses that gap directly, lending the rollout legislative weight beyond the ministry's own mandate. The registry is closer to the moment when the foundation is finally poured.

India's pharmaceutical market at nearly $50 billion, its generic drug leadership, and its ambition to export a replicable digital health stack to the Global South all converge on a single requirement: that the data describing medicines in Indian systems be accurate, consistent, and internationally legible. The Drug Registry, if governed well and adopted across the public and private health ecosystems at scale, delivers that. The harder question is whether adoption — particularly in the private hospital sector, where legacy HMIS platforms resist integration — will keep pace with the registry's technical readiness. That gap is where the real implementation work begins.